Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas.
The management of the older lymphoma patient with cytotoxic chemotherapy requires knowledge of the pharmacologic effects of age and awareness of the diversity of the older population. The most obvious reason for attenuation of treatment intensity in the elderly is the possibility of a decline in hemopoietic reserve. The research of specific therapeutic protocols is needed to cure the elderly lymphoma patients reducing the risk of important toxic effects.